Purpose Changes in drug absorption and first-pass metabolism have been reported
throughout the pediatric age range. Our aim is to characterize both intestinal and hepatic …

To predict first‐pass and systemic cytochrome P450 (CYP) 3A‐mediated metabolism of
midazolam in preterm neonates, a physiological population pharmacokinetic model was …

Midazolam is metabolized by the developmentally regulated intestinal and hepatic drug‐
metabolizing enzyme cytochrome P450 (CYP) 3A4/5. It is frequently administered orally to …

Pediatric physiologically based pharmacokinetics modeling in drug development has grown
in the past decade but uncertainty remains regarding ontogeny of some drug metabolizing …

Background and objective Major changes in cytochrome P450 (CYP) 3A activity may be
expected in the first few months of life with, later, relatively limited changes. In this analysis …

Background: In children, a large variability in pharmacokinetics of midazolam, a cytochrome
P450 3A4/5 (CYP3A4/5) enzyme substrate, has been described, which cannot be explained …

Aims Inflammation and organ failure have been reported to have an impact on cytochrome
P450 (CYP) 3A‐mediated clearance of midazolam in critically ill children. Our aim was to …

Objective To determine in humans the relative roles of intestinal and hepatic metabolism in
the oral first‐pass elimination of a CYP3A substrate using midazolam as a model compound …

Aim: To evaluate the SimCYP simulator ethnicity-specific population model for predicting the
pharmacokinetics of midazolam, a typical CYP3A4/5 substrate, in Chinese after oral …

Recently a framework was presented to assess whether pediatric covariate models for
clearance can be extrapolated between drugs sharing elimination pathways, based on …